Improving ADR Reporting in Jordan: a Qualitative Exploration of Pharmacists' Perspectives

Overview

Journal Front Med (Lausanne)

Date 2025 Jan 21

PMID 39835106

Authors

Amal K Suleiman

Affiliations

Soon will be listed here.

Abstract

Background: Community pharmacists are most accessible to patients. Hence, they have a crucial role in ensuring drug safety by detecting and reporting adverse drug reactions (ADRs). However, there may be gaps in their knowledge of ADR reporting systems and barriers they face in reporting.

Objective: This study aims to assess community pharmacists' knowledge of ADR reporting systems in the Kingdom of Jordan, identify the barriers they face in reporting ADRs, and explore the broader factors that influence their involvement in pharmacovigilance activities.

Methods: In-depth, semi-structured, face-to-face interviews were held with 20 community pharmacists from different regions of Jordan to evaluate their understanding of ADR reporting, the obstacles they encountered, and the elements that could motivate them to report ADRs. The interviews were transcribed and subjected to thematic analysis to find recurrent themes and insights. The thematic analysis highlighted opportunities for continuing education and an absence of formal training as the main barriers to ADR reporting.

Results: Pharmacists reported dissatisfaction with time limits in their hectic work situations and the complexity of reporting procedures, especially the length and information demanded by ADR reporting forms. Another factor influencing low reporting rates was a perceived lack of acknowledgment and feedback. Participants proposed that encouraging ADR reporting with professional recognition or compensation and improving and digitizing the reporting process would promote increased participation.

Conclusion: ADR reporting presents considerable difficulties for community pharmacists in Jordan, mostly because of administrative obstacles and an absence of official support and training. Enhancing pharmacovigilance efforts in Jordan could be achieved by providing incentives, simplifying the reporting procedure, and incorporating reporting into the current pharmacy management software.

References

Li R, Curtain C, Bereznicki L, Zaidi S . Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharm. 2018; 40(4):878-889. PMC: 6132965. DOI: 10.1007/s11096-018-0700-2. View

Starks H, Trinidad S . Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory. Qual Health Res. 2007; 17(10):1372-80. DOI: 10.1177/1049732307307031. View

Onakpoya I, Heneghan C, Aronson J . Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016; 14:10. PMC: 4740994. DOI: 10.1186/s12916-016-0553-2. View

Ogar C, Abiola A, Yuah D, Ibrahim A, Oreagba I, Amadi E . A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016. Pharmaceut Med. 2020; 33(2):145-157. DOI: 10.1007/s40290-019-00267-2. View

Eldridge N, Wang Y, Metersky M, Eckenrode S, Mathew J, Sonnenfeld N . Trends in Adverse Event Rates in Hospitalized Patients, 2010-2019. JAMA. 2022; 328(2):173-183. PMC: 9277501. DOI: 10.1001/jama.2022.9600. View

OCallaghan J, Griffin B, Morris J, Bermingham M . Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. BioDrugs. 2018; 32(3):267-280. PMC: 5990561. DOI: 10.1007/s40259-018-0281-6. View

Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T . Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15-9. PMC: 443443. DOI: 10.1136/bmj.329.7456.15. View

van Grootheest A, van Puijenbroek E, de Jong-van den Berg L . Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002; 11(3):205-10. DOI: 10.1002/pds.702. View

Alshammari T, Almoslem M . Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: A multi-centre cross sectional study. Saudi Pharm J. 2018; 26(7):925-931. PMC: 6218328. DOI: 10.1016/j.jsps.2018.04.012. View

10.

Zondi S, Naidoo P . Perceptions, practices and barriers to reporting of adverse drug reactions among HIV infected patients and their doctors in 3 public sector hospitals of the Ethekwini Metropolitan, Kwa-Zulu Natal: a cross sectional and retrospective analysis. BMC Health Serv Res. 2022; 22(1):1054. PMC: 9389709. DOI: 10.1186/s12913-022-08395-3. View

11.

Alanazi A, Alfadl A, Hussain A . Pharmaceutical Care in the Community Pharmacies of Saudi Arabia: Present Status and Possibilities for Improvement. Saudi J Med Med Sci. 2019; 4(1):9-14. PMC: 6298263. DOI: 10.4103/1658-631X.170881. View

12.

Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider H . Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf. 2000; 22(2):161-8. DOI: 10.2165/00002018-200022020-00007. View

13.

Toklu H, Uysal M . The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharm World Sci. 2008; 30(5):556-62. DOI: 10.1007/s11096-008-9209-4. View

14.

Bouvy J, De Bruin M, Koopmanschap M . Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015; 38(5):437-53. PMC: 4412588. DOI: 10.1007/s40264-015-0281-0. View

15.

Ergun Y, Bekiroglu Ergun T, Toker E, Unal E, Akben M . Knowledge attitude and practice of Turkish health professionals towards pharmacovigilance in a university hospital. Int Health. 2018; 11(3):177-184. DOI: 10.1093/inthealth/ihy073. View

16.

Gray S, Hart L, Perera S, Semla T, Schmader K, Hanlon J . Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults. J Am Geriatr Soc. 2017; 66(2):282-288. PMC: 5809283. DOI: 10.1111/jgs.15195. View

17.

Bhagavathula A, Elnour A, Jamshed S, Shehab A . Health Professionals' Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(3):e0152221. PMC: 4807086. DOI: 10.1371/journal.pone.0152221. View

18.

Mhaidat N, Alshogran O, Altawalbeh S, Jaber J, Banat H, Ahmad D . Patterns of adverse drug reactions in Jordan: a retrospective analysis of the National Pharmacovigilance Data Registry (2015-2021). Expert Opin Drug Saf. 2023; 22(10):957-965. DOI: 10.1080/14740338.2023.2223957. View

19.

Farha R, Hammour K, Rizik M, Aljanabi R, Alsakran L . Effect of educational intervention on healthcare providers knowledge and perception towards pharmacovigilance: A tertiary teaching hospital experience. Saudi Pharm J. 2018; 26(5):611-616. PMC: 6035326. DOI: 10.1016/j.jsps.2018.03.002. View

20.

Jaam M, Naseralallah L, Hussain T, Pawluk S . Pharmacist-led educational interventions provided to healthcare providers to reduce medication errors: A systematic review and meta-analysis. PLoS One. 2021; 16(6):e0253588. PMC: 8221459. DOI: 10.1371/journal.pone.0253588. View